{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T01:39:39Z","timestamp":1792633179218,"version":"4.5.0"},"reference-count":35,"publisher":"MyJove Corporation","issue":"147","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JoVE"],"DOI":"10.3791\/59472","type":"journal-article","created":{"date-parts":[[2019,5,15]],"date-time":"2019-05-15T20:00:33Z","timestamp":1557950433000},"source":"Crossref","is-referenced-by-count":14,"title":["Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs"],"prefix":"10.3791","author":[{"given":"Stefanie","family":"Lindner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Steinebach","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannes","family":"Kehm","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Mangold","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"G\u00fctschow","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Kr\u00f6nke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2098","published-online":{"date-parts":[[2019,5,15]]},"reference":[{"issue":"5971","key":"ref1","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1126\/science.1177319","type":"journal-article","article-title":"Identification of a primary target of thalidomide teratogenicity","volume":"327","author":"Ito","year":"2010","unstructured":"Ito, T. et al. Identification of a primary target of thalidomide teratogenicity. Science. 327 (5971), 1345-1350 (2010).","journal-title":"Science"},{"issue":"11","key":"ref2","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1038\/leu.2012.119","type":"journal-article","article-title":"Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide","volume":"26","author":"Lopez-Girona","year":"2012","unstructured":"Lopez-Girona, A. et al. Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide. Leukemia. 26 (11), 2326-2335 (2012).","journal-title":"Leukemia"},{"issue":"7512","key":"ref3","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/nature13527","type":"journal-article","article-title":"Structure of the DDB1-CRBN E3 ubiquitin ligase in complex with thalidomide","volume":"512","author":"Fischer","year":"2014","unstructured":"Fischer, E. S. et al. Structure of the DDB1-CRBN E3 ubiquitin ligase in complex with thalidomide. Nature. 512 (7512), 49-53 (2014).","journal-title":"Nature"},{"issue":"6","key":"ref4","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1111\/bjh.12708","type":"journal-article","article-title":"Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4(CRBN)","volume":"164","author":"Gandhi","year":"2014","unstructured":"Gandhi, A. K. et al. Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4(CRBN.). British Journal of Haematology. 164 (6), 811-821 (2014).","journal-title":"British Journal of Haematology"},{"issue":"7","key":"ref5","doi-asserted-by":"crossref","first-page":"e941742","DOI":"10.4161\/21624011.2014.941742","type":"journal-article","article-title":"Lenalidomide induces degradation of IKZF1 and IKZF3","volume":"3","author":"Kronke","year":"2014","unstructured":"Kronke, J., Hurst, S. N., & Ebert, B. L. Lenalidomide induces degradation of IKZF1 and IKZF3. Oncoimmunology. 3 (7), e941742 (2014).","journal-title":"Oncoimmunology"},{"issue":"6168","key":"ref6","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1126\/science.1244917","type":"journal-article","article-title":"The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins","volume":"343","author":"Lu","year":"2014","unstructured":"Lu, G. et al. The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins. Science. 343 (6168), 305-309 (2014).","journal-title":"Science"},{"issue":"4","key":"ref7","doi-asserted-by":"crossref","first-page":"683","DOI":"10.3109\/10428194.2012.728597","type":"journal-article","article-title":"Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myeloma","volume":"54","author":"Zhu","year":"2013","unstructured":"Zhu, Y. X., Kortuem, K. M., & Stewart, A. K. Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myeloma. Leukemia & Lymphona. 54 (4), 683-687 (2013).","journal-title":"Leukemia & Lymphona"},{"issue":"9","key":"ref8","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/nsmb.2874","type":"journal-article","article-title":"Structure of the human Cereblon-DDB1-lenalidomide complex reveals basis for responsiveness to thalidomide analogs","volume":"21","author":"Chamberlain","year":"2014","unstructured":"Chamberlain, P. P. et al. Structure of the human Cereblon-DDB1-lenalidomide complex reveals basis for responsiveness to thalidomide analogs. Nature Structural & Molecular Biology. 21 (9), 803-809 (2014).","journal-title":"Nature Structural & Molecular Biology"},{"key":"ref9","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.38430","type":"journal-article","article-title":"Thalidomide promotes degradation of SALL4, a transcription factor implicated in Duane Radial Ray syndrome","volume":"7","author":"Donovan","year":"2018","unstructured":"Donovan, K. A. et al. Thalidomide promotes degradation of SALL4, a transcription factor implicated in Duane Radial Ray syndrome. eLife. 7 (2018).","journal-title":"eLife"},{"issue":"10","key":"ref10","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1038\/s41589-018-0129-x","type":"journal-article","article-title":"SALL4 mediates teratogenicity as a thalidomide-dependent cereblon substrate","volume":"14","author":"Matyskiela","year":"2018","unstructured":"Matyskiela, M. E. et al. SALL4 mediates teratogenicity as a thalidomide-dependent cereblon substrate. Nature Chemical Biology. 14 (10), 981-987 (2018).","journal-title":"Nature Chemical Biology"},{"issue":"7559","key":"ref11","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/nature14610","type":"journal-article","article-title":"Lenalidomide induces ubiquitination and degradation of CK1alpha in del(5q) MDS","volume":"523","author":"Kronke","year":"2015","unstructured":"Kronke, J. et al. Lenalidomide induces ubiquitination and degradation of CK1alpha in del(5q) MDS. Nature. 523 (7559), 183-188 (2015).","journal-title":"Nature"},{"issue":"15","key":"ref12","doi-asserted-by":"crossref","first-page":"8554","DOI":"10.1073\/pnas.141230798","type":"journal-article","article-title":"Protacs: chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation","volume":"98","author":"Sakamoto","year":"2001","unstructured":"Sakamoto, K. M. et al. Protacs: chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation. Proceedings of the National Academy of Sciences of the United States of America. 98 (15), 8554-8559 (2001).","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"12","key":"ref13","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1074\/mcp.T300009-MCP200","type":"journal-article","article-title":"Development of Protacs to target cancer-promoting proteins for ubiquitination and degradation","volume":"2","author":"Sakamoto","year":"2003","unstructured":"Sakamoto, K. M. et al. Development of Protacs to target cancer-promoting proteins for ubiquitination and degradation. Molecular & Cellular Proteomics. 2 (12), 1350-1358 (2003).","journal-title":"Molecular & Cellular Proteomics"},{"issue":"12","key":"ref14","doi-asserted-by":"crossref","first-page":"3748","DOI":"10.1021\/ja039025z","type":"journal-article","article-title":"Chemical genetic control of protein levels: selective in vivo targeted degradation","volume":"126","author":"Schneekloth","year":"2004","unstructured":"Schneekloth, J. S., Jr. et al. Chemical genetic control of protein levels: selective in vivo targeted degradation. Journal of the American Chemical Society. 126 (12), 3748-3754 (2004).","journal-title":"Journal of the American Chemical Society"},{"issue":"4","key":"ref15","doi-asserted-by":"crossref","first-page":"e1700247","DOI":"10.1002\/bies.201700247","type":"journal-article","article-title":"PROTACs: An Emerging Targeting Technique for Protein Degradation in Drug Discovery","volume":"40","author":"Gu","year":"2018","unstructured":"Gu, S., Cui, D., Chen, X., Xiong, X., & Zhao, Y. PROTACs: An Emerging Targeting Technique for Protein Degradation in Drug Discovery. Bioessays. 40 (4), e1700247 (2018).","journal-title":"Bioessays"},{"issue":"7","key":"ref16","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1042\/BCJ20160762","type":"journal-article","article-title":"Chemical approaches to targeted protein degradation through modulation of the ubiquitin-proteasome pathway","volume":"474","author":"Collins","year":"2017","unstructured":"Collins, I., Wang, H., Caldwell, J. J., & Chopra, R. Chemical approaches to targeted protein degradation through modulation of the ubiquitin-proteasome pathway. Biochemical Journal. 474 (7), 1127-1147 (2017).","journal-title":"Biochemical Journal"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.pharmthera.2017.02.027","type":"journal-article","article-title":"Targeted protein degradation by PROTACs","volume":"174","author":"Neklesa","year":"2017","unstructured":"Neklesa, T. K., Winkler, J. D., & Crews, C. M. Targeted protein degradation by PROTACs. Pharmacology & Therapeutics. 174, 138-144 (2017).","journal-title":"Pharmacology & Therapeutics"},{"issue":"6241","key":"ref18","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1126\/science.aab1433","type":"journal-article","article-title":"Phthalimide conjugation as a strategy for in vivo target protein degradation","volume":"348","author":"Winter","year":"2015","unstructured":"Winter, G. E. et al. DRUG DEVELOPMENT. Phthalimide conjugation as a strategy for in vivo target protein degradation. Science. 348 (6241), 1376-1381 (2015).","journal-title":"Science"},{"issue":"1","key":"ref19","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1038\/s41467-017-00954-1","type":"journal-article","article-title":"Homo-PROTACs: bivalent small-molecule dimerizers of the VHL E3 ubiquitin ligase to induce self-degradation","volume":"8","author":"Maniaci","year":"2017","unstructured":"Maniaci, C. et al. Homo-PROTACs: bivalent small-molecule dimerizers of the VHL E3 ubiquitin ligase to induce self-degradation. Nature Communications. 8 (1), 830 (2017).","journal-title":"Nature Communications"},{"key":"ref20","type":"journal-article","article-title":"Identification and Characterization of Von Hippel-Lindau-Recruiting Proteolysis Targeting Chimeras (PROTACs) of TANK-Binding Kinase 1","author":"Crew","year":"2017","unstructured":"Crew, A. P. et al. Identification and Characterization of Von Hippel-Lindau-Recruiting Proteolysis Targeting Chimeras (PROTACs) of TANK-Binding Kinase 1. Journal of Medicinal Chemistry. (2017).","journal-title":"Journal of Medicinal Chemistry"},{"issue":"6","key":"ref21","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.chembiol.2015.05.009","type":"journal-article","article-title":"Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4","volume":"22","author":"Lu","year":"2015","unstructured":"Lu, J. et al. Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4. Chemistry & Biology. 22 (6), 755-763 (2015).","journal-title":"Chemistry & Biology"},{"issue":"12","key":"ref22","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1039\/C8CC09541H","type":"journal-article","article-title":"PROTAC-mediated crosstalk between E3 ligases","volume":"55","author":"Steinebach","year":"2019","unstructured":"Steinebach, C. et al. PROTAC-mediated crosstalk between E3 ligases. Chemical Communications. 55 (12), 1821-1824 (2019).","journal-title":"Chemical Communications"},{"issue":"12","key":"ref23","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1039\/C6MD00347H","type":"journal-article","article-title":"Small molecule-mediated protein knockdown as a new approach to drug discovery","volume":"7","author":"Tinworth","year":"2016","unstructured":"Tinworth, C. P., Lithgow, H., & Churcher, I. Small molecule-mediated protein knockdown as a new approach to drug discovery. Medchemcomm. 7 (12), 2206-2216 (2016).","journal-title":"Medchemcomm"},{"issue":"9","key":"ref24","doi-asserted-by":"crossref","first-page":"2771","DOI":"10.1021\/acschembio.8b00693","type":"journal-article","article-title":"Homo-PROTACs for the Chemical Knockdown of Cereblon","volume":"13","author":"Steinebach","year":"2018","unstructured":"Steinebach, C. et al. Homo-PROTACs for the Chemical Knockdown of Cereblon. ACS Chemical Biology. 13 (9), 2771-2782 (2018).","journal-title":"ACS Chemical Biology"},{"issue":"23","key":"ref25","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1002\/cmdc.201600496","type":"journal-article","article-title":"Synthesis and Antiangiogenic Properties of Tetrafluorophthalimido and Tetrafluorobenzamido Barbituric Acids","volume":"11","author":"Ambrozak","year":"2016","unstructured":"Ambrozak, A. et al. Synthesis and Antiangiogenic Properties of Tetrafluorophthalimido and Tetrafluorobenzamido Barbituric Acids. ChemMedChem. 11 (23), 2621-2629 (2016).","journal-title":"ChemMedChem"},{"key":"ref26","type":"journal-article","article-title":"Discovery of a Small-Molecule Degrader of Bromodomain and Extra-Terminal (BET) Proteins with Picomolar Cellular Potencies and Capable of Achieving Tumor Regression","author":"Zhou","year":"2017","unstructured":"Zhou, B. et al. Discovery of a Small-Molecule Degrader of Bromodomain and Extra-Terminal (BET) Proteins with Picomolar Cellular Potencies and Capable of Achieving Tumor Regression. Journal of Medicinal Chemistry. (2017).","journal-title":"Journal of Medicinal Chemistry"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.ejmech.2018.03.071","type":"journal-article","article-title":"Proteolysis Targeting Chimeras (PROTACs) of Anaplastic Lymphoma Kinase (ALK)","volume":"151","author":"Zhang","year":"2018","unstructured":"Zhang, C. et al. Proteolysis Targeting Chimeras (PROTACs) of Anaplastic Lymphoma Kinase (ALK). European Journal of Medicinal Chemistry. 151, 304-314 (2018).","journal-title":"European Journal of Medicinal Chemistry"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.cbpa.2016.06.031","type":"journal-article","article-title":"Chemical genetics approaches for selective intervention in epigenetics","volume":"33","author":"Runcie","year":"2016","unstructured":"Runcie, A. C., Chan, K. H., Zengerle, M., & Ciulli, A. Chemical genetics approaches for selective intervention in epigenetics. Current Opinion in Chemical Biology. 33, 186-194 (2016).","journal-title":"Current Opinion in Chemical Biology"},{"issue":"6168","key":"ref29","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1126\/science.1244851","type":"journal-article","article-title":"Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells","volume":"343","author":"Kronke","year":"2014","unstructured":"Kronke, J. et al. Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. Science. 343 (6168), 301-305 (2014).","journal-title":"Science"},{"issue":"7","key":"ref30","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1038\/nm.4128","type":"journal-article","article-title":"Immunomodulatory drugs disrupt the cereblon-CD147-MCT1 axis to exert antitumor activity and teratogenicity","volume":"22","author":"Eichner","year":"2016","unstructured":"Eichner, R. et al. Immunomodulatory drugs disrupt the cereblon-CD147-MCT1 axis to exert antitumor activity and teratogenicity. Nature Medicine. 22 (7), 735-743 (2016).","journal-title":"Nature Medicine"},{"issue":"18","key":"ref31","doi-asserted-by":"crossref","first-page":"4771","DOI":"10.1182\/blood-2011-05-356063","type":"journal-article","article-title":"Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide","volume":"118","author":"Zhu","year":"2011","unstructured":"Zhu, Y. X. et al. Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide. Blood. 118 (18), 4771-4779 (2011).","journal-title":"Blood"},{"issue":"9","key":"ref32","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1182\/blood-2016-02-698092","type":"journal-article","article-title":"Targeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBN and Ras pathway genes","volume":"128","author":"Kortum","year":"2016","unstructured":"Kortum, K. M. et al. Targeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBN and Ras pathway genes. Blood. 128 (9), 1226-1233 (2016).","journal-title":"Blood"},{"issue":"1","key":"ref33","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/j.bbrc.2017.11.098","type":"journal-article","article-title":"Cereblon deficiency confers resistance against polymicrobial sepsis by the activation of AMP activated protein kinase and heme-oxygenase-1","volume":"495","author":"Gil","year":"2018","unstructured":"Gil, M. et al. Cereblon deficiency confers resistance against polymicrobial sepsis by the activation of AMP activated protein kinase and heme-oxygenase-1. Biochemical and Biophysical Research Communications. 495 (1), 976-981 (2018).","journal-title":"Biochemical and Biophysical Research Communications"},{"issue":"8","key":"ref34","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1007\/s00424-016-1854-1","type":"journal-article","article-title":"Cereblon in health and disease","volume":"468","author":"Kim","year":"2016","unstructured":"Kim, H. K. et al. Cereblon in health and disease. Pfl\u00fcgers Archiv: European Journal of Physiology. 468 (8), 1299-1309 (2016).","journal-title":"Pfl\u00fcgers Archiv: European Journal of Physiology"},{"issue":"6","key":"ref35","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.2337\/db12-1030","type":"journal-article","article-title":"Disruption of the cereblon gene enhances hepatic AMPK activity and prevents high-fat diet-induced obesity and insulin resistance in mice","volume":"62","author":"Lee","year":"2013","unstructured":"Lee, K. M. et al. Disruption of the cereblon gene enhances hepatic AMPK activity and prevents high-fat diet-induced obesity and insulin resistance in mice. Diabetes. 62 (6), 1855-1864 (2013).","journal-title":"Diabetes"}],"container-title":["Journal of Visualized Experiments"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jove.com\/t\/59472\/chemical-inactivation-e3-ubiquitin-ligase-cereblon-pomalidomide-based","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T01:03:52Z","timestamp":1792631032000},"score":1,"resource":{"primary":{"URL":"https:\/\/app.jove.com\/t\/59472"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,15]]},"references-count":35,"journal-issue":{"issue":"147","published-online":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.3791\/59472","relation":{},"ISSN":["1940-087X"],"issn-type":[{"value":"1940-087X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,15]]}}}